Accident – Death – Obituary News : The Business Research Company Updates Global Pentavalent Market Report for 2024 and Beyond
The Business Research Company has recently released its latest global market report for the pentavalent market, offering valuable insights and projections for the industry up to 2033. The report provides a comprehensive analysis of the market structure, including estimates for various segments and sub-segments, giving businesses a competitive edge in the evolving market landscape.
Market Size and Growth Forecast
The pentavalent market has shown steady growth in recent years, with a projected increase from $2.53 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. Factors contributing to this growth include global immunization initiatives, government vaccination programs, prevention of multiple diseases, public health awareness, and international partnerships and funding.
The market is expected to continue its growth trajectory, reaching $3.17 billion in 2028 at a CAGR of 4.6%. This growth will be driven by ongoing global immunization efforts, expansion of vaccination programs, introduction in new geographies, research and development initiatives, and collaborations for vaccine access. Key trends in the forecast period include global health initiatives and funding support, public awareness and education campaigns, government policies and regulatory frameworks, and technological innovations in vaccine manufacturing.
Market Segmentation
The pentavalent market covered in the report is segmented by type, formulation type, and application. Types include Sodium Stibogluconate and Meglumine Antimoniate, while formulation types consist of Lyophilized and Liquid. Applications encompass Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.
Major Driver – Rising Diphtheria Incidence Boosts Pentavalent Market
The increasing prevalence of diphtheria is expected to drive growth in the pentavalent market. Diphtheria, caused by the bacterium Corynebacterium diphtheriae, is a severe and highly contagious disease that can lead to difficulties with eating and breathing, as well as skin ulcers. The pentavalent vaccine offers protection against diphtheria through a 3-dose schedule, leading to increased demand for pentavalent vaccines. Recent reports from the World Health Organization have highlighted a surge in diphtheria cases, further underscoring the importance of vaccination programs.
Competitive Landscape
Key players in the pentavalent market include Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi SA, and other leading pharmaceutical companies. These companies are driving innovation in the market by developing pentavalent immunization solutions to combat a range of diseases. For example, Pfizer recently received FDA approval for its ‘Penbraya’ pentavalent vaccine, offering protection against five prevalent meningococcal serogroups.
Get Access to the Full Market Report
For more detailed insights into the pentavalent market, access the full market report from The Business Research Company. The report covers market characteristics, trends, strategies, competitor landscape, company profiles, and future outlook for the industry.
Contact The Business Research Company
To learn more about The Business Research Company and its market intelligence services, reach out to their team via email or phone. Stay connected with the latest updates by following them on LinkedIn, Twitter, Facebook, and YouTube.
About The Business Research Company
The Business Research Company is a global market intelligence firm specializing in company, market, and consumer research across various industries. With offices in the UK, US, and India, and a network of researchers in 28 countries, TBRC offers comprehensive insights to help businesses navigate the competitive market landscape.
This release was published on openPR..